FMP
Sirona Biochem Corp.
SRBCF
PNK
Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. Sirona Biochem Corp. has a research collaboration agreement with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop antiviral library of compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.
0.0187 USD
-0.0024 (-12.83%)
Operating Data
Year
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Revenue
98.25k
76.51k
193.99k
486.34k
25.17k
30.4k
36.71k
44.33k
53.54k
64.66k
Revenue %
-
-22.12
153.54
150.7
-94.82
20.76
20.76
20.76
20.76
Ebitda
-
-2.98M
-1.66M
-2.54M
-1.69M
-24.32k
-29.37k
-35.47k
-42.83k
-51.72k
Ebitda %
-
-3.9k
-857.85
-523.24
-6.71k
-80
-80
-80
-80
Ebit
-3.04M
-2.99M
-1.67M
-2.55M
-1.7M
-30.4k
-36.71k
-44.33k
-53.54k
-64.66k
Ebit %
-3.09k
-3.9k
-861.38
-524.59
-6.74k
-100
-100
-100
-100
Depreciation
3.04M
7.02k
6.85k
6.58k
7.03k
8.63k
10.42k
12.59k
15.2k
18.36k
Depreciation %
3.09k
9.17
3.53
1.35
27.92
28.39
28.39
28.39
28.39
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
